Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
A method for obtaining improved bone quality in a vertebrate, including mammal and bird, the method comprising administering to a vertebrate, including mammal and bird, in a sufficient amount and/or at a sufficient rate to enable a desired effect, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof. Also contemplated is a method for modulating bone quality in a vertebrate, including mammal and bird, comprising administering to the vertebrate, including mammal and bird, in the need thereof, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof, for modulating the bone quality as well as a compositions for use in treatment.
1. A method of reducing the risk of or treating osteoporosis, the method comprising administering a mono-metal salt of alpha-ketoglutaric acid (AKG), a di-metal salt of AKG, or an amino acid salt of AKG, to a vertebrate in need thereof wherein the mono-metal salt or the di-metal salt is a pharmaceutically acceptable salt.
2. The method according to claim 1 , comprising administering a composition comprising the member and a pharmaceutically acceptable carrier and/or additives to the vertebrate.
3. The method according to claim 2 , wherein the composition is a food or a feed supplement.
4. The method according to claim 2 wherein the composition is a dietary supplement and/or a component in the form of solid food and/or beverage.
5. The method according to claim 1 , comprising administering a therapeutically effective amount of the member to the vertebrate.
6. The method according to claim 5 , wherein the therapeutically effective amount is 0.01-0.2 g/kg bodyweight per daily dose.
7. A method of improving bone quality in a vertebrate, including a mammal and a bird, comprising administering a member selected from the group consisting of a mono-metal salt of alpha-ketoglutaric acid (AKG), a di-metal salt of AKG, an amino acid salt of AKG, and mixtures thereof, to a vertebrate in the need thereof wherein the mono-metal salt or the di-metal salt is a pharmaceutically acceptable salt.
8. The method according to claim 7 , comprising administering a composition comprising the member and a pharmaceutically acceptable carrier and/or additives to the vertebrate.
9. The method according to claim 8 , wherein the composition is a food or a feed supplement.
10. The method according to claim 8 , wherein the composition is a dietary supplement and/or a component in form of solid food and/or beverage.
11. The method according to claim 7 , comprising administering a therapeutically effective amount of the member to the vertebrate.
12. The method according to claim 11 , wherein the therapeutically effective amount is 0.01-0.2 g/kg bodyweight per daily dose.
13. The method according to claim 1 , wherein the mono- or di-metal salt of alpha-ketoglutaric acid (AKG) is administered.
14. The method according to claim 1 , wherein the amino acid is ornitine, arginine, glutamine, glutamic acid or leucine.
15. The method according to claim 2 , wherein the mono- or di-metal salt of alpha-ketoglutaric acid (AKG) is administered.
16. The method according to claim 2 , wherein the amino acid is ornitine, arginine, glutamine, glutamic acid or leucine.
17. The method according to claim 5 , wherein the mono- or di-metal salt of alpha-ketoglutaric acid (AKG) is administered.
18. The method according to claim 5 , wherein the amino acid is ornitine, arginine, glutamine, glutamic acid or leucine.
19. The method according to claim 7 , wherein the mono- or di-metal salt of alpha-ketoglutaric acid (AKG) is administered.
20. The method according to claim 7 , wherein the amino acid is ornitine, arginine, glutamine, glutamic acid or leucine.
21. The method according to claim 8 , wherein the mono- or di-metal salt of alpha-ketoglutaric acid (AKG) is administered.
22. The method according to claim 8 , wherein the amino acid is ornitine, arginine, glutamine, glutamic acid or leucine.
23. The method according to claim 11 , wherein the mono- or di-metal salt of alpha-ketoglutaric acid (AKG) is administered.
24. The method according to claim 11 , wherein the amino acid is ornitine, arginine, glutamine, glutamic acid or leucine.
25. The method according to claim 1 , wherein the vertebrate is affected with osteoporosis.
26. The method according to claim 1 , wherein the vertebrate is not affected with osteoporosis.
27. A method of treating osteopenia and preventing osteoporosis, the method comprising administering a mono-metal salt of alpha-ketoglutaric acid (AKG), a di-metal salt of AKG, or an amino acid salt of AKG, to a vertebrate in need thereof wherein the mono-metal salt or the di-metal salt is a pharmaceutically acceptable salt.
28. The method according to claim 27 , comprising administering a composition comprising the member and a pharmaceutically acceptable carrier and/or additives to the vertebrate.
29. The method according to claim 28 , wherein the composition is a food or a feed supplement.
30. The method according to claim 28 , wherein the composition is a dietary supplement and/or a component in the form of solid food and/or beverage.
31. The method according to claim 27 , comprising administering a therapeutically effective amount of the member to the vertebrate.
32. The method according to claim 31 , wherein the therapeutically effective amount is 0.01-0.2 g/kg bodyweight per daily dose.
33. The method according to claim 27 , wherein the mono- or di-metal salt of alpha-ketoglutaric acid (AKG) is administered.
34. The method according to claim 27 , wherein the amino acid is ornitine, arginine, glutamine, glutamic acid or leucine.